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ABSTRACT
In human breast cancer, estrogen receptor-α (ERα) suppresses epithelial–
mesenchymal transition (EMT) and stemness, two crucial parameters for tumor 
metastasis; however, the underlying mechanism by which ERα regulates these two 
processes remains largely unknown. Bmi1, the polycomb group protein B lymphoma 
Mo-MLV insertion region 1 homolog, regulates EMT transition, maintains the self-
renewal capacity of stem cells, and is frequently overexpressed in human cancers. 
In the present study, ERα upregulated the expression of the epithelial marker, 
E-cadherin, in breast cancer cells through the transcriptional down-regulation of 
Bmi1. Furthermore, ERα overexpression suppressed the migration, invasion, and EMT 
of breast cancer cells. Notably, overexpression of ERα significantly decreased the 
CD44high/CD24low cell population and inhibited the capacity for mammosphere formation 
in ERα-negative breast cancer cells. In addition, overexpression of Bmi1 attenuated 
the ERα-mediated suppression of EMT and cell stemness. Immunohistochemistry 
revealed an inverse association of ERα and Bmi1 expression in human breast cancer 
tissue. Taken together, our findings suggest that ERα inhibits EMT and stemness 
through the downregulation of Bmi1.
INTRODUCTION
Of all cancers, that of the breast is the most 
common for women, with most breast cancer-related 
deaths involving widespread metastasis [1]. Estrogen 
receptor-α (ERα) is a nuclear receptor that is activated by 
the sex hormone, estrogen; it regulates the transcription 
of estrogen-responsive genes in diverse target cells. 
Ligand binding induces a conformational change within 
ERα, thus promoting dimerization and high-affinity 
binding to specific estrogen-responsive elements (EREs) 
located within the promoter of target genes [2]. ERα is 
an important prognostic indicator in breast cancer [3]. 
ERα signaling promotes the growth of primary breast 
cancers, but can also antagonize signaling pathways that 
lead to epithelial–mesenchymal transition (EMT) [1, 2, 
4–7]. ERα-positive breast cancer cells appear to contain a 
relatively small subpopulation of breast cancer stem cells 
[8, 9]. Post-EMT breast cancer cells express cancer stem 
cell markers, including Bmi1, but show decreased ERα 
expression [10, 11]. However, the mechanisms by which 
ERα regulates EMT, as well as inhibits stemness in breast 
cancer, remain to be explored.
In EMT, epithelial cells lose their polarity and 
acquire the migratory and invasive properties of 
mesenchymal cells. Cell-to-cell adhesion is mediated 
by cadherins such as E-cadherin, which provides a 
structural support for cell–cell attachment. Thus, a loss 
Oncotarget21705www.impactjournals.com/oncotarget
of E-cadherin expression can cause a loss of polarity of 
epithelial cells and is considered a fundamental event 
in EMT [12, 13]. In addition to its crucial role in the 
differentiation of many tissues and organs, EMT has also 
been shown to cause organ fibrosis and promote carcinoma 
progression through a variety of mechanisms [13]. Recent 
reports suggest a direct link between EMT and the gain 
of stem-like properties [12, 13]. Induction of EMT not 
only allows cancer cells to disseminate from the primary 
tumor, but also promotes their self-renewal capability. 
In breast cancer, EMT is associated with cancer stem 
cell properties, including the expression of a stem cell-
associated CD44high/CD24low antigenic profile, and self-
renewal capabilities [10]. Despite this, the molecular 
pathways linking EMT to the acquisition of stem cell 
properties remain, as yet, largely undefined.
Increasing evidence suggests that the polycomb 
group of transcription factor proteins plays a crucial role 
in cancer development and recurrence. Of these, Bmi1 is 
a member of the polycomb-repressive complex 1, which 
is strongly involved in the self-renewal of stem cells 
and is associated with a number of human malignancies 
such as oropharyngeal cancer, neuroblastoma and 
melanoma [14–18]. Bmi1 maintains the self-renewal 
of both normal and malignant human mammary stem 
cells [19], suppresses E-cadherin, and enhances stemness 
in head and neck cancer cells [20]. Bmi1 also plays an 
important role in both EMT and stemness processes in 
human nasopharyngeal and pancreatic cancers [21, 22]. 
In a previous study, ERα was demonstrated to up-regulate 
the expression of E-cadherin both directly and indirectly 
[2, 7, 23, 24]. However, whether EMT inhibition by ERα 
is mediated through a direct/indirect upregulation of 
E-cadherin remains poorly understood, and further, the 
regulatory mechanism of Bmi1 in cancer cells and its role 
in metastasis are largely unknown.
We hypothesized that ERα may upregulate 
E-cadherin through a Bmi1-mediated pathway. We 
investigated this process in vitro in breast cancer cells, and 
in vivo in a mouse model and human breast cancer tissues.
RESULTS
Estrogen hormone (E2) and ERα downregulates 
Bmi1 expression and increases E-cadherin 
expression in breast cancer cells
As was previously reported, post-EMT breast cancer 
cells express cancer stem cell markers, including Bmi1, but 
display decreased ERα expression [1]. In order to quantify 
Bmi1 expression in breast cancer cells, we detected Bmi1 
protein expression by Western blot in various breast cancer 
cell lines. We found that Bmi1 expression was higher in 
three ERα-negative breast cancer cell lines (SKBR3, 
BT549, and MDA-MB-231) than in ERα-positive 
T47D or BT474 cells (Figure 1A). To compare Bmi1 
mRNA expression in these lines, real-time RT-PCR 
was performed, with β-actin used as an internal control. 
Consistent with Bmi1 protein expression, Bmi1 mRNA 
levels were 2 to 3 fold higher in ERα-negative breast 
cancer cell lines than in in ERα-positive cells (Figure 1B).
Because both protein and mRNA levels of Bmi1 
were decreased in ERα-positive T47D cells relative to 
ERα-negative breast cancer cell lines, we determined 
whether ERα signaling played a role in Bmi1 expression. 
T47D cells cultured in estrogen-depleted medium were 
treated with various concentrations of E2. After 24 or 72 h, 
Bmi1 protein and mRNA levels were dose-dependently 
downregulated by E2 (Supplemental Figures 1A, 1B; 
Figures 1C, 1D, respectively). When the cells were treated 
with E2 at 10−7 M for 72 h, Bmi1 mRNA levels were 
significantly reduced by approximately 70% (Figure 1D; 
P < 0.05), and protein levels were decreased by more than 
90% (Figure 1C).
To further investigate the impact of ERα on Bmi1, 
we silenced endogenous ERα in T47D cells using siRNA 
and examined Bmi1 and E-cadherin expression. As shown 
in Figures 1E and 1F, silencing endogenous ERα in T47D 
cells led to the significant up-regulation of Bmi1 and 
significant down-regulation of E-cadherin at both protein 
and mRNA levels (P < 0.05), respectively, in a dose-
dependent manner.
To investigate the effect of ERα on Bmi1 expression 
in an ERα-negative breast cancer cell line, we stably 
transfected the recombinant vector pEGFP-C1-ERα, or an 
empty vector, into ERα-negative BT549 cells. ERα protein 
and mRNA levels (P < 0.05) were increased in pEGFP-
C1-ERα-, but not control, vector-transfected BT549 cells 
(Figures 1G and 1H, respectively). We further analyzed the 
expression of Bmi1 and E-cadherin. Bmi1 was markedly 
downregulated and E-cadherin was upregulated at both 
the protein level, and significantly, at the mRNA level in 
pEGFP-C1-ERα, as compared with pEGFP-C1 transfected 
BT549 cells (Figures 1G, 1H; P < 0.05 for mRNA).
ERα down-regulates Bmi1 expression by directly 
binding to the BMI1 promoter
Based on our previous findings that Bmi1 
expression is transcriptionally regulated by ERα signaling, 
we addressed whether ERα can directly bind to the 
regulatory regions of the BMI1 promoter. To determine 
the binding site, we searched for specific EREs located 
within the BMI1 promoter. We did not find classical ERE 
sites but instead found a half-ERE site at position −178 
to −174 (Figure 2A). To investigate whether ERα could 
form a complex with the BMI1 promoter, we performed 
a chromatin immunoprecipitation (ChIP) assay with 
primers covering the BMI1 promoter region. We used a far 
upstream region, beyond the half-ERE site, in the BMI1 
promoter as a negative control. ERα bound to the region 
between positions −237 to −106 containing the half-ERE 
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site, but not the region between positions −1184 to −1023, 
which did not contain the ERE/half-ERE binding site 
(Figure 2B).
Electrophoretic mobility shift assay (EMSA) 
revealed an ERα-binding band after the incubation of 
nuclear extracts from BT549 cells overexpressing ERα 
Figure 1: E2 and ERα downregulates Bmi1 expression and increases E-cadherin expression in breast cancer cells. A–B. 
Western blot (A) and quantitative real-time RT-PCR analysis (B) of protein and mRNA expression of Bmi1 in ERα-positive T47D and 
BT474 cells, and ERα-negative breast cancer cells (SKBR3, BT549 and MDA-MB-231). C–D. T47D cells were maintained in phenol red-
free DMEM with 10% dextran-coated charcoal-treated FBS for 48 h, and cells then treated with either ethanol vehicle or E2 (10 or 100 nM) 
for 72 h. Cells were harvested and analyzed for Bmi1 mRNA and protein levels. Data are mean ± SEM (n = 3). *P < 0.05 compared with 
ethanol vehicle (Student’s t test). E–F. Western blot (E) and quantitative RT-PCR analysis (F) of protein and mRNA levels in T47D cells 
transfected with control siRNA, ERα siRNA-1 (5 and 50 nM) or ERα siRNA-2 (50 nM). G–H. ERα, Bmi1 and E-cadherin protein and 
mRNA levels in BT549 cells stably transfected with the indicated vectors. Protein expression was normalized to β-actin mRNA. *P < 0.05 
compared with control cells (Student’s t test).
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Figure 2: Bmi1 expression is directly regulated by ERα. A. A schematic representation of the BMI1 promoter region, with 
or without the half-ERE site for ERα. Precipitated DNA was amplified by PCR with specific primers for regions 1–2. B. Chromatin 
immunoprecipitation (ChIP) assay involved normal IgG (IgG), or anti-ERα (ERα) antibody to identify the ERα binding site on the BMI1 
promoter in T47D cells. C. Electrophoretic mobility shift assay (EMSA). Nuclear extracts from pEGFP-C1-ERα-transfected BT549 cells 
were incubated with a probe labeled at its 3′-end with biotin from the BMI1 promoter region containing the ERα binding site (lanes 1–8). 
Unlabeled probe (lane 1) or mutant oligonucleotides (lane 3) were added at 50-fold greater concentrations than that of the labeled probe. In 
the non-specific binding assay, 25 or 125 ng of poly (dI: dC) (lanes 4–5), normal IgG (lane 6), or anti-Twist1 antibody (lane 7) was added. 
For the supershift assay, the addition of anti-ERα antibody resulted in a supershifted band (lane 8). D. T47D cells were co-transfected 
with a BMI1 promoter construct (pXP2-BMI1–Luc1000) and ERα siRNA (3 or 15 nM). E. T47D cells were transfected with a BMI1 
promoter construct (pXP2-BMI1–Luc1000) and treated with either ethanol vehicle (EtOH) or 100 nM E2 (E2) for 24 h. F. T47D cells were 
transfected with pXP2-BMI1–mutant and treated with either ethanol vehicle (EtOH) or 100 nM E2 (E2) for 24 h. G. BT549 cells were  
co-transfected with pXP2-BMI1–Luc1000 and either pEGFP-C1 or pEGFP-C1-ERα. H. BT549 cells were co-transfected with  
pXP2-BMI1–mutant and either pEGFP-C1 or pEGFP-C1-ERα. E–H, All cells were co-transfected with Renilla luciferase plasmid. 
Luciferase activity was normalized to that of Renilla. *P < 0.05 (Student’s t test) compared with control cells. Data are mean ± SEM (n = 3).
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with labeled oligonucleotides containing the half-ERE 
from the BMI1 regulatory region; a supershifted band was 
seen after the addition of an anti-ERα-specific antibody to 
the mixture (Figure 2C). The addition of excess amounts 
of unlabeled oligonucleotides containing the half-ERE 
outcompeted and abolished the binding activity of ERα, 
but not the addition of mutant half-ERE–containing 
unlabeled oligonucleotides or non-specific competition 
by poly (dI:dC). No supershifted band was seen after the 
addition of an unrelated antibody, normal IgG, or anti-
Twist1 antibody, which binds to the E box of the BMI1 
promoter.
To determine the direct regulation of BMI1 by 
ERα, we used a luciferase reporter vector that included 
the region from −1000 to −1 of the BMI1 gene. A dual 
luciferase reporter assay was used to investigate BMI1 
promoter activity in ERα-silenced T47D cells or ERα-
overexpressing BT549 cells by co-transfection with the 
BMI1 promoter and Renilla luciferase reporter genes. 
Transfection with ERα siRNA significantly increased 
BMI1 promoter activity 2- to 3.5-fold in T47D cells 
in a dose-dependent manner (Figure 2D; P < 0.05). E2 
administration decreased wild-type BMI1 promoter 
activity to 0.5-fold (Figure 2E; P < 0.05) but did not show 
any effect on the mutant BMI1 promoter (Figure 2F). 
Similarly, ectopic ERα overexpression significantly 
decreased BMI1 promoter activity to 0.5-fold in BT549 
cells (Figure 2G; P < 0.05), but showed no effect on 
mutant BMI1 promoter activity (Figure 2H). These 
results demonstrated that ERα directly repressed BMI1 
transcription by specifically binding to the promoter 
region of the BMI1 gene.
ERα suppresses EMT and stemness in breast 
cancer cells
We next examined BT549 cells, stably transfected 
with either pEGFP-C1 or pEGFP-C1-ERα vector, for 
morphological changes indicating EMT (Figure 3A). 
pEGFP-C1 BT549 cells possessed a fibroblast-like 
morphology and displayed pronounced cellular scattering, 
while pEGFP-C1-ERα BT549 cells expressing ERα 
showed a morphological conversion from a spindle-
shaped, mesenchymal morphology to a cuboidal, epithelial 
morphology (Figure 3A). Through seeding small amounts 
of cells, apparent morphological change could be seen after 
48 h culture (Supplemental Figure 2). In contrast, silencing 
endogenous ERα expression in T47D cells resulted in a 
partial loss of epithelial characteristics (Figure 3B).
To further investigate the impact of ERα on EMT, 
we determined migratory and invasive behaviors in 
ERα stably-transfected BT549 cells. The healing of 
wounded areas was significantly slower by about 65% in 
pEGFP-C1-ERα, compared to pEGFP-C1, BT549 cells 
(Figure 3C; P < 0.05). Overexpression of ERα in BT549 
cells significantly decreased the level of migration to 
about 50% of the control (Figure 3D; P < 0.05). Matrigel 
invasion chamber assays revealed that overexpression 
of ERα markedly reduced, to about 35% of capacity, the 
invasiveness of BT549 cells (Figure 3E: P < 0.05).
Post-EMT mammary epithelial cells show an 
increased capability of mammosphere formation and 
an increased CD44high/CD24low cell population, both of 
which are characteristics of normal mammary and breast 
cancer stem cells [14–16]. The mammosphere formation 
assay showed a significant decrease in both the size and 
number of mammospheres in pEGFP-C1-ERα BT549 
cells (Figure 3F; P < 0.05 and Supplemental Figure 3). 
To determine whether ERα expression decreased the 
cancer stem cell–like cell population by suppressing 
EMT, we analyzed the CD44high/CD24low cell population 
in ERα stably-transfected BT549 cells. Most of the 
control pEGFP-C1 BT549 cells showed a CD44high/
CD24low phenotype, which was significantly decreased, 
from 76% to 7% of the cell population in pEGFP-C1-ERα 
BT549 cells (Figure 3G; P < 0.05). These results indicate 
that ERα suppresses both the expression of cell surface 
markers and functional characteristics associated with 
cancer stem cells.
ERα decreased the metastatic ability of BT549 
cells in vivo
To test whether ERα overexpression indeed 
decreases the metastatic ability of BT549 cells in vivo, a 
tail vein metastatic model was established in BALB/c nude 
mice. At 6 weeks following the injection of tumor cells, 
animals were sacrificed and lung metastasis was examined 
by H&E staining. Three of the five mice implanted with 
BT549 cells developed lung metastases. In contrast, mice 
implanted with BT549 cells overexpressing ERα showed 
no evident metastatic nodules in lungs (Figures 4A, 4B). 
Experimental and control groups did not show metastasis 
in the liver (data not shown).
Restoration of Bmi1 expression reverses  
ERα-mediated suppression of EMT and stemness
Next, we investigated the role of Bmi1 in 
ERα-mediated suppression of EMT and stemness 
properties in breast cancer cells. A Bmi1 expression 
vector or empty vector was transiently transfected into 
pEGFP-C1-ERα BT549 cells; restoration of Bmi1 
expression resulted in the loss of E-cadherin expression 
(Figures 5A, 5B), significantly increased migration 
or invasion (Figures 5C, 5D; P < 0.05 for both), and 
significantly increased mammosphere-forming ability 
(Figure 5E; P < 0.05). Restoration of Bmi1 expression 
did not affect the protein level of ERα (Figure 5B), and 
we therefore conclude that ERα is an upstream regulator 
of Bmi1, with no feedback regulation between ERα 
and Bmi1.
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Figure 3: ERα suppresses EMT and cell stemness. A. Morphology of pEGFP-C1 and pEGFP-C1-ERα BT549 cells. B. Morphology 
of T47D cells transfected with control or ERα siRNA. C. Wound healing assay in pEGFP-C1 or pEGFP-C1-ERα BT549 cells.  
D–E. Migration and invasion assays of pEGFP-C1 and pEGFP-C1-ERα BT549 cells. Representative images of migrating (D) or invading 
(E) cells are shown. F. Representative images of mammosphere forming units (MFUs) observed in pEGFP-C1 and pEGFP-C1-ERα BT549 
cells. Data are mean ± SEM (n = 3). G. FACS analysis of cell-surface markers CD44 and CD24 in pEGFP-C1 and pEGFP-C1-ERα 
BT549 cells. Data are mean ± SEM (n = 3). *P < 0.05 compared to pEGFP-C1 BT549 cells (Student’s t test). Magnification, 400 × (A–B, 
D–F); 100 × (C).
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Figure 4: ERα expression reduces the metastasis of BT549 cells. A. H&E staining of metastatic nodules (red box) in mouse lung 
tissue. Magnification, 100× (upper); 200× (bottom). Bar = 50 μM. B. Number of mice with pulmonary nodules (n = 5).
Figure 5: Restoration of Bmi1 expression reverts ERα-suppressed EMT and stemness. A. Western blot analysis of Bmi1 
protein in BT549 cells transfected with the indicated vectors. B. Western blot analysis of ERα, Bmi1 and E-cadherin protein levels in 
pEGFP-C1 or pEGFP-C1-ERα BT549 cells transiently transfected with the indicated vectors. C–D. Migration and invasion assays. 
Representative images of migrating (C) or invading cells (D) are shown. E. Morphology and quantification of mammospheres. Ctrl: 
pEGFP-C1 BT549 cells transiently transfected with control plasmid pcDNA3; ERα+Ctrl: pEGFP-C1-ERα BT549 cells transiently 
transfected with pcDNA3; ERα+Bmi1: pEGFP-C1-ERα BT549 cells transiently transfected with pcDNA3-BMI1. *P < 0.05, pEGFP- 
C1-ERα BT549 cells transfected with pcDNA3 (ERα+Ctrl) compared with pEGFP-C1 BT549 cells transfected with pcDNA3 (Ctrl). 
#P < 0.05, pEGFP-C1-ERα BT549 cells transfected with pcDNA3 (ERα+Ctrl) compared with pEGFP-C1-ERα BT549 cells transfected 
with pcDNA3 BMI1 (ERα+Bmi1) (Student’s t test). Data are mean ± SEM (n = 3). Magnification, 400× (C–E).
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Bmi1 expression is negatively associated 
with ERα and E-cadherin levels in 
human breast cancer
We further analyzed the mRNA levels of Bmi1 and 
E-cadherin in 58 human breast cancer samples. Bmi1 
mRNA levels were significantly lower in ERα-positive 
than in ERα-negative tissues (Figure 6A; P < 0.05), but 
E-cadherin mRNA levels were significantly higher in 
ERα-positive than in ERα-negative tissues (Figure 6B; 
P < 0.05). Furthermore, immunohistochemistry staining 
for Bmi1, ERα and E-cadherin revealed that Bmi1 
expression was inversely associated with ERα and 
E-cadherin levels in human breast cancer specimens in 
a significant manner (Table 1 and Figure 6C; P < 0.05). 
We demonstrated an inverse linear correlation of ERα or 
E-cadherin expression, with Bmi1 expression, when the 
percentage of positively stained cells for each protein was 
determined in human breast cancer tissues (Figures 6D 
and 6E; P < 0.05). These results support a model of 
ERα interacting with the Bmi1 locus, leading to the 
transcriptional repression of Bmi1 for the downregulation 
of E-cadherin.
DISCUSSION
Breast cancer is the most commonly diagnosed 
cancer in women and remains one of the leading causes 
of death [1]. Most breast cancer-related deaths occur 
after extensive metastasis, during which EMT endows 
cancer cells with increased migration and invasive 
capabilities. Since ERα has been shown to suppress 
EMT, efforts to elucidate the molecular mechanisms by 
which ERα regulates EMT, as well as inhibits stemness, 
in breast cancer are warranted in order to develop novel 
treatments for this common type of cancer. In the current 
study, we have demonstrated that ERα can suppress 
Bmi1 expression by transcriptional repression, and 
inhibit EMT and stemness in breast cancer through an 
ERα–Bmi1–E-cadherin pathway.
The loss of E-cadherin expression is considered to 
be a fundamental event in EMT [13]. Several mechanisms, 
including transcriptional repression and methylation of 
the promoter, have been shown to repress E-cadherin 
expression. Many transcription factors, such as Snail, 
Slug and Zeb1, can bind to the E-cadherin promoter and 
directly repress its transcription [25–28], whereas other 
factors, such as Twist1 and FoxC2, can repress E-cadherin 
indirectly. This results in a disrupted polarity of epithelial 
cells and induced EMT [29, 30], thus maintaining the 
mesenchymal phenotype and enhancing the invasiveness 
and metastasis of cancer cells [31].
Bmi1 can downregulate E-cadherin expression and 
induce EMT in head and neck cancer by directly binding 
to E-box consensus sequences in the promoter region 
of E-cadherin [20]. Bmi1 can also indirectly repress 
E-cadherin expression by activating Snail in breast [32] 
and nasopharyngeal cancer [21]. In breast cancer, Bmi1 
and E-cadherin levels were inversely related, while Bmi1 
expression inversely correlated with the prognosis [32]. 
Although numerous studies have demonstrated that the 
regulation of E-cadherin can be mediated by ERα, and 
that the loss of E-cadherin was regulated by Bmi1, no 
studies have outlined the involvement of Bmi1 in an ERα-
mediated E-cadherin regulation and EMT transition.
The presence of ERα represents a epithelial 
phenotype in the breast. Previous studies suggested that 
ERα upregulates several epithelial markers, such as 
E-cadherin, in breast cancer cells. In studying the role 
of Bmi1 in hormone-dependent and -independent breast 
cancer cells, we found that Bmi1 mRNA and protein 
levels were lower in ERα-positive than in ERα-negative 
cells. Furthermore, estrogen stimulation downregulated 
Bmi1 expression in hormone-dependent breast cancer 
cells, while in hormone-independent cells, Bmi1 was 
downregulated by ERα overexpression. When ERα 
expression was silenced by RNA interference, Bmi1 
became upregulated. These findings suggest that ERα 
modulates the Bmi1 signaling pathway.
ERα has previously been shown to bind to the 
ERE/half-ERE region in the promoter of its downstream 
genes to regulate gene expression [33, 34]. For instance, 
ERα can repress Slug transcription by binding to the 
half-ERE element in the Slug promoter to regulate 
Table 1: Association of Bmi1, ERα and E-cadherin expression in human breast cancer tissues
n
Bmi1
P value 
Negative (%) Positive (%)
ERα
 Negative 26 13 (50.0) 13 (50.0) 0.003
 Positive 32 28 (87.5) 4 (12.5)
E-cadherin
 Negative 28 16 (57.1) 12 (42.9) 0.043
 Positive 30 25 (83.3) 5 (16.7)
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E-cadherin expression and EMT [2, 7]. Interestingly, 
the BMI1 promoter sequence includes a half-site ERE 
element (TGACC). Evidence that ERα directly binds to 
the TGACC site in the BMI1 promoter suggests that ERα-
mediated Bmi1 suppression is indeed regulated at the 
transcriptional level. This conclusion is further supported 
by our dual luciferase reporter gene assay revealing 
increased/decreased activity of a BMI1 promoter-driven 
reporter gene in ERα silenced/overexpressing breast 
cancer cells. Our findings indicate that ERα suppresses 
Bmi1 expression by directly binding to the half-ERE site 
of the BMI1 promoter, thereby demonstrating a novel 
pathway by which ERα suppresses migration, invasion, 
and EMT in breast cancer cells, in addition to modulating 
Slug [2, 7] and NF-κB [6] pathways. Interestingly, a 
recent article by Wang et al. reported that ERα bound 
Figure 6: Association of Bmi1 and E-cadherin expression in 58 human breast cancer tissues. A, B. Relative mRNA levels 
of Bmi1 (A) and E-cadherin (B) with ERα-negative and ERα-positive expression in breast cancer tissues. *P < 0.05 (Student’s t test). 
C. Representative fields of positive ERα, negative Bmi1 and positive E-cadherin (upper row) and negative ERα, positive Bmi1, and 
negative E-cadherin (lower row). Magnification, 400× (C) D. Scatter plot of Bmi1 and ERα positive, immunohistochemically stained 
percentages of cells in human breast cancer tissues. E. Scatter plot of Bmi1 and E-cadherin positive, immunohistochemically stained 
percentages of cells in human breast cancer tissues (Spearman’s Rank Correlation Test).
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to the promoter of Bmi1, as also identified by our study, 
suggesting that the ERα could transcriptionally modulate 
Bmi1 expression [35]. In contrast to our findings, 
however, Wang’s study found that Bmi1 expression was 
upregulated by the overexpression of ERα in another ERα-
positive breast cancer cell line, MCF-7, while depletion of 
this protein caused a down-regulation of Bmi1. Whether 
this well-demonstrated, opposing regulation is cell line-
specific needs to be investigated in future studies.
Song et al. showed that Bmi1 could inhibit 
phosphatase and tensin homologs, induce EMT and also 
regulate the self-renewal and differentiation of stem 
cells in human nasopharyngeal epithelial cells [21]. In 
pancreatic cancer, the EMT-activator, Zeb1, maintains 
stemness of cells, in part, through Bmi1 [22]. In our study, 
the elevated expression of ERα decreased the CD44high/
CD24low cell population in breast cancer cells and 
inhibited the cells’ capacity to form mammospheres. Most 
importantly, restoring Bmi1 expression reversed the ERα-
mediated suppression of EMT and stemness. The current 
findings highlight the critical role of Bmi1 in regulating 
both EMT and stemness in breast cancer cells. Although 
ERα expression represses the stemness of cancer cells, 
the underlying mechanism of ERα in regulating stemness 
has not been thoroughly explored. ERα may modulate 
the stemness of breast cancer cells by suppressing Bmi1 
expression, and may therefore be considered an inhibitor 
of circulating and migrating cancer stem cells.
In summary, our results demonstrate that ERα can 
suppress EMT in human breast cancer cells through the 
transcriptional down-regulation of Bmi1 and its down-
stream genes. An inverse relationship between ERα and 
Bmi1 expression further supports the epithelial phenotype 
of ERα-positive tumors, or the mesenchymal phenotype 
of ERα-negative tumors, as being most likely regulated 
via the ERα–Bmi1–E-cadherin axis. Our findings provide 
a novel mechanistic insight into how ERα regulates EMT 
and may be of value in developing new biomarkers for the 
prognosis of breast cancer.
MATERIALS AND METHODS
Cell lines, antibodies and plasmids
BT474, T47D, MDA-MB-231, BT549 and 
SKBR3 breast cancer cell lines were purchased from 
the Committee on Type Culture Collection of the 
Chinese Academy of Science (Shanghai, China). The 
pEGFP-C1-ERα plasmid was purchased from Addgene 
(Cambridge, MA, USA), and pcDNA3-BMI1 plasmid was 
a gift from Dr. MH Yang (Institute of Clinical Medicine, 
National Yang-Ming University, Taipei city, Taiwan) [20]. 
A wild type BMI1 promoter (pXP2-BMI1–Luc1000) 
from −1023 to −1 was constructed and a mutant 
BMI1 promoter was generated by replacing a TGACC 
(−178–174) sequence in the wild type BMI1 promoter 
with a GACCC sequence. The following antibodies were 
used in this study: anti-E-cadherin (DAKO, Glostrup, 
Denmark; NCH-38), anti-Bmi1 (Abcam, Cambridge, UK; 
ab126783), anti-ERα (Santa Cruz Biotechnology, CA, 
USA; sc-543), anti-β-actin (Santa Cruz Biotechnology, 
Dallas, TX, USA; sc-4777), PE-conjugated anti-CD24 
(BD Biosciences, Bedford, MA, USA; ML5), APC-
conjugated anti-CD44 (BD Pharmigen, San Jose, CA, 
USA; G44–26), PE-conjugated mouse IgG (BD; G155–
178), and APC-conjugated mouse IgG (BD; 27–35).
Transfections
We transfected 5 μg of the vectors, pEGFP-C1 or 
pEGFP-C1-ERα, containing full-length human ERα, into 
BT549 cells growing in 10-cm tissue culture plates using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). 
Stable clones were selected and established by culturing in 
Dulbecco’s modified Eagle’s medium (DMEM) plus 10% 
fetal bovine serum (FBS) containing 0.8 mg/mL G418 
(Merck & Co., Whitehouse Station, NJ, USA). To clarify 
the role of Bmi1, 5 μg of pcDNA3 or pcDNA3-BMI1 
was transfected into pEGFP-C1-ERα stable cells growing 
in 10-cm tissue culture plates for 48 h. ERα siRNA and 
scrambled siRNA were synthesized by Genepharma 
Biotech (Shanghai, China). ERα siRNA-1 sequences were 
as follows [2]: 5′-CGAGUAUGAUCCUACCAGAII-3′ 
(sense) and 5′-UCUGGUAGGAUCAUACUCGGA-3′ 
(antisense); siRNA-2 sequences: 
5′-AAGCUACUGUUUGCUCCUAACTT-3′ (sense) 
and 5′-GUUAGGAGCAAACAGUAGCUUTT-3′ 
(antisense). Scrambled siRNA sequences were 
5′-UUCUCCCGAACGUUCACGU-3′ (sense) and 
5′-ACGUGACACGUUCGGAGAA-3′ (antisense). 
Transfection of siRNA involved the use of Lipofectamine 
2000. Briefly, 5 or 50 nmol/L ERα siRNA or scrambled 
siRNA was transfected into cultured T47D cells (at 50% 
confluence) for 48 h.
RNA isolation and RT-PCR
TRIzol reagent (Invitrogen, Carlsbad, CA) was used 
to isolate total RNA from cultured cells or fresh-frozen 
breast cancer tissue. The PrimeScript RT Reagent Kit 
(Takara, Dalian, China) with random primers was used 
to synthesize cDNA. PCR reactions involved 2 μL cDNA 
and the ABI PRISM 7300 Sequence Detection System 
(Applied Biosystems, Foster City, CA, USA). Expression 
was normalized to that of the β-actin housekeeping gene 
as an internal control. The primer sequences were for 
β-actin, 5′-AGCGAGCATCCCCCAAAGTT-3′ (sense) 
and 5′-GGGCACGAAGGCTCATCATT-3′ (antisense); 
ERα, 5′-TGCTTCAGGCTACCATTATGGA-3′ (sense) 
and 5′-TGGCTGGACACATATAGTCGTT-3′ (antisense); 
Bmi1, 5′-GCTGCCAATGGCTCTAATGAA-3′ (sense); 
and 5′-TGCTGGGCATCGTAAGTATCTT-3′ (antisense); 
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E-cadherin, 5′-AAAGGCCCATTTCCTAAAAACCT-3′ 
(sense) and 5′-TGCGTTCTCTATCCAGAGGCT-3′.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as previously 
described [36]. In brief, T47D cells at 80% to 90% 
confluence growing in 10-cm dishes were treated with 
1% formaldehyde for 10 min to cross-link proteins to 
DNA, and then sonicated four times for 10 sec by use 
of a sonicator with a microtip in a 1.5-mL tube. The 
resultant lysate underwent immunoprecipitation (IP) 
with 1 μg polyclonal anti-ERα antibody. Normal 
IgG was used as an IP control, and the supernatant 
was used as an input control. Immunoprecipitated 
complexes were collected by adding protein A/G-
agarose/salmon sperm DNA beads and incubating 
samples for 2 h at 4ºC. The beads were then treated 
with RNase A (50 μg/mL) and proteinase K. DNA was 
extracted with phenol/chloroform and co-precipitated 
with glycogen, dissolved in 25 μL TE buffer, and 
subjected to PCR amplification for ERα binding sites 
in the BMI1 promoter using specific primers: BMI1–1, 
5′-CGGGCCTGACTACACCGACAC-3′ (sense), and 
5′-GGAAACTGACACCGGCTCCAA-3′ (antisense); 
BMI1–2, GCAGAGGAAAACCAGAAACG-3′ (sense) 
and 5′-TGGGCAGTATCTTTCCCTCTT-3′ (antisense). 
The acquired DNA was resolved on a 2% agarose gel and 
stained with Goldview.
Electrophoretic mobility shift assay (EMSA)
Oligonucleotides 
(5′-AGCACGTGACCCGCTGGG-3′) containing putative 
binding sequences of ERα were labeled at the 3′-end with 
biotin and incubated with nuclear extracts harvested from 
BT549 cells transfected with pEGFP-C1-ERα. The binding 
reaction (20 min at room temperature) was carried out in a 
final volume of 20 μL containing the biotin-labeled probe 
(20 fmol), with nuclear extract according to the LightShift 
Chemiluminescent EMSA Kit (Beyotime Biotech, Haimen, 
China) manufacturer’s protocol. In supershift experiments, 
the nuclear extract was preincubated with anti-ERα antibody 
for 30 min on ice. In non-specific binding assays, poly 
(dI:dC), nonspecific antibodies, including normal IgG or anti-
Twist1 antibody, were added instead of anti-ERα antibody. 
In the competition assay, excess amounts of unlabeled 
competitors, including putative binding sequences and mutant 
sequences (5′-AGCACGGACCCCGCTGGG-3′), were 
added before the labeled probes. After binding, the samples 
were separated on 6% non-denaturing polyacrylamide gels 
and visualized by enhanced chemiluminescence.
Cell migration and invasion assays
A modified cell migration assay was performed 
using BT549 cells stably transfected with pEGFP-C1 
or pEGFP-C1-ERα cells as described previously [26]. 
An 8-μm pore-size Boyden chamber (BD) was used for 
in vitro migration and invasion assays. Cells (5 × 104) 
incubated in DMEM supplemented with 1% bovine serum 
albumin were plated in the upper chamber, and 10% fetal 
bovine serum was added to DMEM in the lower chamber 
as a chemoattractant. A BD BioCoat Matrigel Invasion 
Chamber (BD) was used for the invasion assay. After 
24 h (migration assay) or 72 h (invasion assay), cells on 
the upper side of the filter were removed, and cells that 
remained adherent to the underside of membrane were 
fixed in 4% formaldehyde and stained with crystal violet 
dye. Five random fields per membrane were photographed 
with the use of a BX51 microscope (Olympus, Tokyo, 
Japan) at ×400 magnification. The cells were counted and 
the mean number of the five fields was calculated to obtain 
a representative number of cells that had migrated/invaded 
across the membrane. Three independent experiments 
were performed for each assay.
Wound healing assay
BT549 cells stably transfected with pEGFP-C1 or 
pEGFP-C1-ERα were seeded in 6-well plates at a density 
of 3 × 105 cells/well. Cells were then serum-starved for 
24 h, and a linear wound was created in the confluent 
monolayer by use of a pipette tip. Wound healing was 
photographed at 24 h intervals. Experiments were done 
in triplicate, and three random fields of each well were 
recorded.
Flow-cytometric analysis of CD44 and 
CD24 expression
To analyze CD44 and CD24 expression, cells 
were trypsinized and suspended in phosphate buffered 
saline (PBS), plus 1% fetal bovine serum, at a density of 
106 cells/100 μL. Cells were incubated at 4°C in the dark 
for 40 min with PE-conjugated anti-CD44 antibody and 
APC-conjugated anti-CD24 antibody, or their respective 
isotype controls, at concentrations recommended by the 
manufacturer. Labeled cells were washed twice with 
PBS, then fixed in PBS containing 1% paraformaldehyde 
and analyzed with the use of a FACSCalibur flow 
cytometer (BD).
Mammosphere assay
Single cells were plated at a density of 
1,000 cells/mL in 96-well ultralow attachment plates 
(Corning, New York, USA). Cells were grown in 
serum-free DMEM/F12 supplemented with B27 
(1:50, Invitrogen), 20 ng/mL endothelial growth factor, 
20 ng/mL basic fibroblast growth factor and 4 μg/mL 
heparin (Sigma, St. Louis, MO, USA). Cells were 
cultured for 7 d, and mammospheres with >50 μm 
diameter were counted.
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Immunohistochemistry (IHC) of human 
breast cancer tissues
Human breast cancer specimens were obtained 
from 58 patients who underwent breast cancer surgery 
at the Cancer Hospital of Shantou University Medical 
College, China between 2010 and 2011. Written informed 
consent was obtained from each patient, and the study was 
approved by the Hospital Research Ethics Committee.
Serial formalin-fixed and paraffin-embedded tissues 
were sectioned at a 4 μm thickness, deparaffinized, and 
rehydrated in gradients of high percentage ethanol to 
distilled water. For quenching endogenous peroxidase 
activity, sections were immersed in 3% hydrogen 
peroxide for 15 min at room temperature. Antigen retrieval 
involved boiling in 10 mM sodium citrate buffer (pH 6) 
for 3 min in a pressure cooker, followed by cooling to 
room temperature. Sections were then incubated with the 
primary antibody at 4ºC overnight, washed three times in 
PBS for 5 min, and incubated with horseradish peroxidase-
conjugated goat anti-mouse/rabbit IgG antibody (ZSGB-
Bio, Beijing, China) at room temperature for 30 min, 
followed by 3, 3′-diaminobenzidine tetra-hydrochloride 
(DAB) staining. Sections were lightly counterstained with 
hematoxylin.
The expression of ERα, Bmi1 and E-cadherin was 
detected using specific antibodies, with normal mouse or 
rabbit IgG (Santa Cruz Biotechnology) used as the 
negative control. Cases were considered as positive for 
ERα if nuclear immunoreactivity was present in ≥10% of 
tumor cells. For nuclear Bmi1 staining, the percentage of 
stained cells was categorized into 0 to 3+ as previously 
described [20]: 0, no staining; 1+, 1–25%; 2+, 25–50%; 
and 3+, > 50% nuclear staining. Only 3+ was considered 
as a positive IHC result. E-cadherin expression was 
interpreted as either normal (strong) or aberrant (reduced 
or absent). Aberrant staining was defined as either negative 
staining or <50% membranous staining of the population 
of cells examined. Normal staining was defined as ≥50% 
membranous staining of the cancer cells [37]. The percent 
of positively stained cells was evaluated, in the same 
section of tissue, to analyze the correlation between Bmi1 
and ERα or E-cadherin.
In vivo metastasis in mice
Eight- to 10-week-old female BALB/C nude mice 
were intravenously injected, via the tail vein, with 5 × 107 
pEGFP-C1 or pEGFP-C1-ERα stable cells in 0.1 mL PBS 
(5 mice for each group). Six weeks after injection, mice 
were euthanized to grossly detect metastases. The visceral 
organs, such as lung and liver, were fixed with formalin, 
then paraffin-embedded and stained with hematoxylin 
and eosin (H&E). Metastatic lesions were evaluated by 
microscopic examination. The animal study was approved 
by the Institutional Animal Care and Use Committee of 
Shantou University Medical College.
Statistical analysis
Statistical analysis was performed using SPSS 
16.0 (SPSS Inc., Chicago, IL, USA). Differences among 
variables were assessed by χ2 analysis, Spearman’s Rank 
Correlation Test or 2-tailed Student’s t tests. Data were 
presented as the mean ± SEM unless otherwise indicated. 
Two-sided P < 0.05 was considered statistically significant. 
Each experiment was performed at least three times.
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